Jin Zhinan, Tucker Kathryn, Lin Xiaoyan, Kao C Cheng, Shaw Ken, Tan Hua, Symons Julian, Behera Ishani, Rajwanshi Vivek K, Dyatkina Natalia, Wang Guangyi, Beigelman Leo, Deval Jerome
Alios BioPharma Inc., South San Francisco, California, USA
Alios BioPharma Inc., South San Francisco, California, USA.
Antimicrob Agents Chemother. 2015 Dec;59(12):7504-16. doi: 10.1128/AAC.01391-15. Epub 2015 Sep 21.
Norovirus (NoV) is a positive-sense single-stranded RNA virus that causes acute gastroenteritis and is responsible for 200,000 deaths per year worldwide. No effective vaccine or treatment is available. Recent studies have shown that the nucleoside analogs favipiravir (T-705) and 2'-C-methyl-cytidine (2CM-C) inhibit NoV replication in vitro and in animal models, but their precise mechanism of action is unknown. We evaluated the molecular interactions between nucleoside triphosphates and NoV RNA-dependent RNA polymerase (NoVpol), the enzyme responsible for replication and transcription of NoV genomic RNA. We found that T-705 ribonucleoside triphosphate (RTP) and 2CM-C triphosphate (2CM-CTP) equally inhibited human and mouse NoVpol activities at concentrations resulting in 50% of maximum inhibition (IC50s) in the low micromolar range. 2CM-CTP inhibited the viral polymerases by competing directly with natural CTP during primer elongation, whereas T-705 RTP competed mostly with ATP and GTP at the initiation and elongation steps. Incorporation of 2CM-CTP into viral RNA blocked subsequent RNA synthesis, whereas T-705 RTP did not cause immediate chain termination of NoVpol. 2CM-CTP and T-705 RTP displayed low levels of enzyme selectivity, as they were both recognized as substrates by human mitochondrial RNA polymerase. The level of discrimination by the human enzyme was increased with a novel analog of T-705 RTP containing a 2'-C-methyl substitution. Collectively, our data suggest that 2CM-C inhibits replication of NoV by acting as a classic chain terminator, while T-705 may inhibit the virus by multiple mechanisms of action. Understanding the precise mechanism of action of anti-NoV compounds could provide a rational basis for optimizing their inhibition potencies and selectivities.
诺如病毒(NoV)是一种正链单链RNA病毒,可引起急性肠胃炎,在全球每年导致20万人死亡。目前尚无有效的疫苗或治疗方法。最近的研究表明,核苷类似物法匹拉韦(T-705)和2'-C-甲基胞苷(2CM-C)在体外和动物模型中可抑制NoV复制,但其确切作用机制尚不清楚。我们评估了三磷酸核苷与NoV RNA依赖性RNA聚合酶(NoVpol)之间的分子相互作用,NoVpol是负责NoV基因组RNA复制和转录的酶。我们发现,T-705核糖核苷三磷酸(RTP)和2CM-C三磷酸(2CM-CTP)在低微摩尔范围内导致最大抑制率50%(IC50)的浓度下,同等程度地抑制人和小鼠的NoVpol活性。2CM-CTP在引物延伸过程中通过直接与天然CTP竞争来抑制病毒聚合酶,而T-705 RTP在起始和延伸步骤主要与ATP和GTP竞争。将2CM-CTP掺入病毒RNA会阻断后续的RNA合成,而T-705 RTP不会导致NoVpol立即链终止。2CM-CTP和T-705 RTP表现出较低的酶选择性水平,因为它们都被人线粒体RNA聚合酶识别为底物。含有2'-C-甲基取代的T-705 RTP新型类似物增加了人酶的识别水平。总体而言,我们的数据表明,2CM-C通过作为经典的链终止剂来抑制NoV复制,而T-705可能通过多种作用机制来抑制病毒。了解抗NoV化合物的确切作用机制可为优化其抑制效力和选择性提供合理依据。